Revolutionizing Cancer Treatment: OncoBay Clinical Joins The Leukemia & Lymphoma Society’s Beat AML® Master Clinical Trial

Raleigh, NC – April 14, 2023 | OncoBay Clinical, a leading oncology-focused full-service CRO, is pleased to announce its collaboration with The Leukemia & Lymphoma Society (LLS) on its groundbreaking Beat AML® Master Clinical Trial, the first collaborative precision medicine clinical trial for a blood cancer. Launched in 2016, it is now revolutionizing treatment for acute myeloid leukemia (AML), one of the deadliest blood cancers.

The LLS-led Beat AML® Master Clinical Trial, among the first cancer clinical trials to be sponsored by a nonprofit, brings together a broad global collaboration of the best and brightest clinicians, cancer centers, pharmaceutical companies, and operational and technology partners, all unified to fundamentally change the treatment approach to AML. The trial has generated impressive results, showing superior survival rates and better quality of life when patients receive targeted treatment matched to the genetic mutations of their cancer in place of standard chemotherapy treatment.

LLS has selected OncoBay Clinical as the clinical CRO because of its excellent track record for successfully managing complex oncology trials, utilizing the extensive know-how of its expert staff and its access to cutting-edge technology. This enables OncoBay to provide superior data-driven trial management services that ensure high-quality results for the Beat AML® Master Clinical Trial. All these factors combined make OncoBay Clinical an optimal choice for providing the services needed for the Beat AML® Master Clinical Trial.

“We are honored to have been chosen as the CRO for this groundbreaking clinical trial. OncoBay is committed to embracing new and innovative approaches to research, and we are proud that The Leukemia & Lymphoma Society, the global leader in creating a world without blood cancer, has recognized our expertise,” said Dannelle Palmer, COO of OncoBay.

“Our partners are critical to the success of the Beat AML Master Clinical Trial, and we are pleased that OncoBay Clinical is joining this unprecedented global collaboration in our quest to change the treatment paradigm for patients with acute myeloid leukemia,” said Len Rosenberg, PhD, RPh, Head of Clinical Operations at The Leukemia & Lymphoma Society. “As we continue to innovate and build on the success of this trial, we are confident that the patients enrolled will benefit from the expertise and experience of OncoBay’s team of oncology professionals and cutting-edge technology.”

This study is yet another example of OncoBay’s commitment to advancing medicine and delivering results that improve the lives of patients around the world. By partnering with The Leukemia & Lymphoma Society on this critical endeavor, OncoBay looks forward to supporting researchers, clinicians, and patients as they develop new solutions to fight cancer.

For more information on the Beat AML® Master Clinical Trial, visit

About OncoBay
OncoBay Clinical is a global boutique contract research organization (CRO) specializing in immuno-oncology/cell therapy and other complex oncology programs. OncoBay offers strategic and full- service custom-curated solutions for global pharmaceutical and biotech companies looking to advance their product or device. Originated from Moffitt Cancer Center, OncoBay embeds scientific expertise, operational excellence and integration of technology including AI analytics to drive quality and data integrity. Built on years of oncology expertise, an advanced technology framework, a highly aligned site network, and a skilled team of experienced professionals, OncoBay is committed to operational excellence from start to finish. For more information, visit and follow us on Facebook, Twitter and LinkedIn.

About The Leukemia & Lymphoma Society
The Leukemia & Lymphoma Society® (LLS) is a global leader in the fight against blood cancer. The LLS mission: Cure leukemia, lymphoma, Hodgkin’s disease and myeloma, and improve the quality of life of patients and their families. LLS funds lifesaving blood cancer research around the world, provides free information and support services, and is the voice for all blood cancer patients seeking access to quality, affordable, coordinated care.

Founded in 1949 and headquartered in Rye Brook, NY, LLS has regions throughout the United States and Canada. To learn more, visit Patients should contact the Information Resource Center at (800) 955-4572, Monday through Friday, 9 a.m. to 9 p.m. ET.

For additional information visit Follow us on Facebook, Twitter, Instagram, and LinkedIn.

LLS is one of Fast Company’s “2022 Brands That Matter.“ As the only cancer organization on the list, LLS stands out among brands around the world for its relevancy, cultural impact, ingenuity, and mission impact.

About the Beat AML® Master Clinical Trial

The Beat AML® Master Clinical Trial is the first collaborative precision medicine clinical trial in a blood cancer. Launched in 2016 and focused on newly diagnosed patients aged 60 or older, the trial uses advanced genomic technology to match patients to the most promising targeted treatment based on their unique genetic mutations. The trial tests multiple therapies in multiple study arms simultaneously under a “Master Trial” protocol that not only has the power to bring new therapies to acute myeloid leukemia patients faster, but also has the potential to stand as a model for future clinical trials. The trial has already generated strong results, showing superior survival rates and better quality of life when genomic analysis is used to match patients to targeted therapies.

Take Advantage of OncoBay’s Innovative Approach


Submit a Request for Proposal

Submit Proposal

OncoBay is now Kapadi


Once three entities – OncoBay Clinical, Clinscience, and Exom Group s.r.l – now we stand as one, bringing forth a symphony of expertise and seamless operations. To celebrate our unity, we re-brand under the banner of Kapadi, and embark on a new chapter of exceptional service in oncology clinical research.

Kapadi is not just a name; it's a testament to our fusion. It signifies the our standing as a global CRO powerhouse committed to accelerating groundbreaking cancer therapies that uplift patients worldwide. From conceptualizing studies, navigating regulations, and analyzing data, we provide a comprehensive array of services designed to empower your oncology clinical trials.




This pop-up will auto-close in 10 seconds.

This will close in 5 seconds